Giant cell arteriitis (temporal arteriitis, cranial arteriitis). Clinical, histology and treatment;Riesenzellarteriitis (arteriitis temporalis, arteriitis cranialis). Klinik, histologie und therapie

Ophthalmologe

Volumn 103, Issue 4, 2006, Pages 296-301

  Ness T ^a   Auw Hadrich C ^a   Schmidt, D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Arteritis temporalis; Giant cell arteritis; Histology; Therapy

Indexed keywords

C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; FIBRINOGEN; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

BLOOD VESSEL BIOPSY; CLAUDICATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HEADACHE; HISTOLOGY; HUMAN; MYALGIA; RETINA ARTERY OCCLUSION; REVIEW; STEROID THERAPY; SYMPTOM; TEMPORAL ARTERITIS; THROMBOCYTE; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

EID: 33645811689     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-006-1324-9     Document Type: Review

References (72)

1. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120: 987-992
2. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG (1993) Visual prognosis in giant cell arteritis. Ophthalmology 100: 550-555
3. Andersson R, Malmvall BE, Bengtsson BA (1986) Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 220: 465-469
4. Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 79: 309-315
5. Baldursson O, Steinsson K, Bjornsson J, Lie JT (1994) Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 37: 1007-1012
6. Bhatti MT, Tabandeh H (2001) Giant cell arteritis: diagnosis and management. Curr Opin Ophthalmol 12: 393-399
7. Boesen P, Sorensen SF (1987) Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985. Arthritis Rheum 30: 294-299
8. Calamia KT, Hunder GG (1981) Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 24: 1414-1418
9. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44: 2933-2935
10. Cantini F, Niccoli L, Storri L et al. (2004) Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 33: 294-301
11. Caselli RJ, Hunder GG (1997) Giant cell (temporal) arteritis. Neurol Clin 15: 893-902
12. Chevalet P, Barrier JH, Pottier P et al. (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow up study of 164 patients. J Rheumatol 27: 1484-1491
13. Cid MC, Font C, Oristrell J et al. (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41: 26-32
14. Danesh-Meyer HV, Savino PJ, Eagle RC, Kubis KC, Sergott RC (2000) Low diagnostic yield with second biopsies in suspected giant cell arteritis. J Neuroophthalmol 20: 213-215
15. Desmet GD, Knockaert DC, Bobbaers HJ (1990) Temporal arteritis: the silent presentation and delay in diagnosis. J Intern Med 227: 237-240
16. Evans JM, Hunder GG (2000) Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 26: 493-515
17. Ferraccioli GF, Di Poi E, Damato R (2000) Steroid sparing therapeutic approaches to polymyalgia rheumatica - giant cell arteritis. State of the art and perspectives. Clin Exp Rheumatol 18: 58-60
18. Gardiner PV, Griffiths ID (1990) Sudden death after treatment with pulsed methylprednisolone. BMJ 300: 125
19. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, Uriarte E (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41: 1497-1504
20. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J et al. (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 79: 283-292
21. Hayreh SS (1990) Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management. Eye 4(Pt 1): 25-41
22. Hayreh SS (1997) Anterior ischemic optic neuropathy. Clin Neurosci 4: 251-263
23. Hayreh SS (2000) Steroid therapy for visual loss in patients with giant-cell arteritis. Lancet 355: 1572-1573
24. Hayreh SS (2004) Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye 18: 1188-1206
25. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B (1997) Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 123: 285-296
26. Hayreh SS, Podhajsky PA, Zimmerman B (1998) Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 125: 521-526
27. Hayreh SS, Podhajsky PA, Zimmerman B (1998) Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125: 509-520
28. Hayreh SS, Zimmerman B (2003) Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 217: 239-259
29. Hayreh SS, Zimmerman B (2003) Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110: 1204-1215
30. Hazleman B (2000) Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Clin Exp Rheumatol 18: 29-31
31. Hoffman GS, Cid MC, Hellmann DB et al. (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46: 1309-1318
32. Horton B (1932) An undescribed form of arteritis of the temporal vessels. Proc Mayo Clin 7: 700-701
33. Hunder GG (1997) Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 81: 195-219
34. Hunder GG (2000) Classification/diagnostic criteria for GCA/PMR. Clin Exp Rheumatol 18: 4-5
35. Hunder GG, Bloch DA, Michel BA et al. (1990)The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33: 1122-1128
36. Hutchinson J (1890) On a peculiar form of thrombotic of the aged which sometimes productive of gangrene. Arch Surg 1: 323-329
37. Jonasson F, Cullen JF, Elton RA (1979) Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 24: 111-117
38. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134: 106-114
39. Launay D, Hachulla E (2004) [Inflammatory aortitis]. Presse Med 33: 1334-1340
40. Lessell S (2000) Bilateral temporal artery biopsies in giant cell arteritis. J Neuroophthalmol 20: 220-221
41. Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, Vidal E (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111: 211-217
42. Liu GT, Glaser JS, Schatz NJ, Smith JL (1994) Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 101: 1779-1785
43. Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 100: 193-196
44. Murgatroyd H, Milne A (2001) Positive temporal artery biopsy in a patient on therapeutic doses of steroids for six years. Eye 15: 250-251
45. Myles AB, Perera T, Ridley MG (1992) Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 31: 103-105
46. Nesher G, Rubinow A, Sonnenblick M (1997) Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol 15: 303-306
47. Nesher G, Sonnenblick M, Friedlander Y (1994) Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 21: 1283-1286
48. Ness T, Schmidt D (2005) Arteriitis temporalis: Temporalarterienbiopsie, Anamnese und Blutwerte. Zeitschr prakt Augenheilkd 26: 327-332
49. Nordborg E (2000) Epidemiology of biopsy-positive giant cell arteritis: an overview. Clin Exp Rheumatol 18: 15-17
50. Nordborg E, Bengtsson BA (1989) Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 299: 549-550
51. Nordborg E, Nordborg C (2003) Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology (Oxford) 42: 413-421
52. Pless M, Rizzo JF, Lamkin JC, Lessell S (2000) Concordance of bilateral temporal artery biopsy in giant cell arteritis. J Neuroophthalmol 20: 216-218
53. Poller DN, van Wyk Q, Jeffrey MJ (2000) The importance of skip lesions in temporal arteritis. J Clin Pathol 53: 137-139
54. Rahman W, Rahman FZ (2005) Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 50: 415-428
55. Reich KA, Giansiracusa DF, Strongwater SL (1990) Neurologic manifestations of giant cell arteritis. Am J Med 89: 67-72
56. Ruegg S, Engelter S, Jeanneret C, Hetzel A, Probst A, Steck AJ, Lyrer P (2003) Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature. Medicine (Baltimore) 82: 1-12
57. Saag KG, Emkey R, Schnitzer TJ et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339: 292-299
58. Sailler L (2004) [What have we learned about giant cell arteritis during the last decade?]. Rev Med Interne 25: 816-825
59. Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347: 261-271
60. Salvarani C, Cantini F, Boiardi L, Hunder GG (2003) Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 21: 23-28
61. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG (1995) Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 38: 369-373
62. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG (1995)The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 123: 192-194
63. Salvarani C, Hunder GG (2001) Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum 45: 140-145
64. Salvarani C, Macchioni PL, Tartoni PL et al. (1987) Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 5: 205-215
65. Sandercock PA, Warlow CP, Jones LN, Starkey IR (1989) Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 298: 75-80
66. Schmidt D (2003) [Cranial arteritis - An Overview]. Klin Monatsbl Augenheilkd 220: 579-617
67. Schmidt D (2005) Ocular ischemia syndrome - a malignant course of giant cell arteritis. Eur J Med Res 10: 233-242
68. Schmidt D, Adelmann G (2001) The course of the occipital artery - an anatomical investigation for biopsy in suspected vasculitis. Eur J Med Res 6: 235-241
69. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19: 495-501
70. Turbin RE, Kupersmith MJ (1999) Giant Cell Arteritis. Curr Treat Options Neurol 1: 49-56
71. Weyand CM, Bartley GB (1997) Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 123: 392-395
72. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ (2000) Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43: 1041-1048